Disease Modeling Core
疾病建模核心
基本信息
- 批准号:10392981
- 负责人:
- 金额:$ 17.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AdultBeta CellBiological AssayBiological ModelsCRISPR/Cas technologyCell Differentiation processCell LineCell modelCellsClinicalClustered Regularly Interspaced Short Palindromic RepeatsCommunitiesComplexDiabetes MellitusDiseaseDisease modelEnsureEnzyme-Linked Immunosorbent AssayFingerprintGene ExpressionGenerationsGenesGenetic ModelsGenome engineeringGoalsHumanHuman Cell LineImmunotherapyIn VitroIndividualInfrastructureInsulin-Dependent Diabetes MellitusKaryotype determination procedureLaboratoriesLibrariesLiverLuciferasesMedicalMicrosatellite RepeatsMinisatellite RepeatsMissionModelingMolecularMycoplasmaNon-Insulin-Dependent Diabetes MellitusOrganoidsPancreasPancreatic ductPatientsPeripheral Blood Mononuclear CellPluripotent Stem CellsPoint MutationProceduresProtocols documentationQuality ControlReagentReporterReporter GenesReproducibilityResearchResearch PersonnelResourcesReverse Transcriptase Polymerase Chain ReactionSamplingScientistSecureServicesStandardizationSystemTechnologyTestingTimeTissue ModelTissue ProcurementsTissuesTrainingTranslationsTransplantationUnited States National Institutes of HealthValidationadult stem cellassay developmentbasebiobankcell repositorycell typecostcost effectivedata sharingdesigndirected differentiationfunctional genomicsgene correctiongenome editinghuman diseasehuman embryonic stem cellhuman modelhuman stem cellshuman tissuehumanized mousein vitro Modelin vivoinduced pluripotent stem cellinnovationmembermouse modelnoveloverexpressionpluripotencypre-clinicalprogramssearchable databasesmall hairpin RNAstem cell modelstem cell technologystem cellstranslational scientist
项目摘要
DISEASE MODELING CORE
PROJECT SUMMARY/ABSTRACT
The overall mission of the Disease Modeling Core (DM core) is to provide diabetes researchers with access to
novel human stem cell-derived in vitro cell models for investigating cellular and molecular features of both Type
1 and Type 2 diabetes. Recent progress in stem cell, organoid culture, gene editing and directed differentiation
technologies has afforded opportunities to develop state-of-the-art pre-clinical human models. However,
because of the complex experimental protocols and specialized reagents used, together with the considerable
up-front costs and time required to develop these sophisticated stem cell-based models, it is not practical nor
cost-effective to develop these models in individual laboratories. The goal of DM core is to provide the expertise,
infrastructure and access to novel human model systems and technologies to DRC investigators. To help
overcome the obstacles faced by basic scientists and clinical researchers who wish to establish human stem cell
approaches in their laboratories, we will provide expertise, resources and training in start-of-the-art stem cell
technologies together with rigorous quality control testing, validation standardization and authentication all model
platforms and reagents. This goal will be achieved in three ways: 1) providing access and training in current and
emerging pluripotent and adult stem cell technologies for in vitro human disease modeling, including the use of
organoids; 2) providing access, training and implementation of genome editing technology, directed cell
differentiation/programming, and gene expression systems; and 3) providing validation, authentication and data
sharing of all DM-related technologies. Thus, the overall mission of this core is to facilitate access, generation
and usage of novel human stem cell-derived in vitro models to promote basic and translational innovative
diabetes research at UC AMC.
疾病建模核心
项目总结/摘要
疾病建模核心(DM核心)的总体使命是为糖尿病研究人员提供
用于研究两种类型的细胞和分子特征的新型人干细胞衍生的体外细胞模型
2型糖尿病的治疗方法干细胞、类器官培养、基因编辑和定向分化研究进展
技术为开发最先进的临床前人体模型提供了机会。然而,在这方面,
由于复杂的实验方案和使用的专用试剂,以及相当大的
由于开发这些复杂的基于干细胞的模型所需的前期成本和时间,
在个别实验室开发这些模型具有成本效益。DM核心的目标是提供专业知识,
基础设施和获得新的人体模型系统和技术的DRC调查。帮助
克服基础科学家和临床研究人员希望建立人类干细胞所面临的障碍
在他们的实验室中,我们将提供最先进的干细胞技术的专业知识,资源和培训。
技术加上严格的质量控制测试,验证标准化和认证所有模型
平台和试剂。这一目标将通过三种方式实现:1)提供现有和
用于体外人类疾病建模的新兴多能和成体干细胞技术,包括使用
类器官; 2)提供基因组编辑技术的获取、培训和实施,定向细胞
分化/编程和基因表达系统;以及3)提供验证、认证和数据
分享所有与DM相关的技术。因此,该核心的总体使命是促进访问、生成
和使用新的人类干细胞衍生的体外模型,以促进基础和翻译创新
加州大学AMC分校的糖尿病研究
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER J DEMPSEY其他文献
PETER J DEMPSEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER J DEMPSEY', 18)}}的其他基金
ADAM10 in Intestinal Homeostasis and Regeneration
ADAM10 在肠道稳态和再生中的作用
- 批准号:
8734396 - 财政年份:2012
- 资助金额:
$ 17.82万 - 项目类别:
ADAM10 in Intestinal Homeostasis and Regeneration
ADAM10 在肠道稳态和再生中的作用
- 批准号:
8475585 - 财政年份:2012
- 资助金额:
$ 17.82万 - 项目类别:
ADAM10 in Intestinal Homeostasis and Regeneration
ADAM10 在肠道稳态和再生中的作用
- 批准号:
8371729 - 财政年份:2012
- 资助金额:
$ 17.82万 - 项目类别:
ADAM10 in Intestinal Homeostasis and Regeneration
ADAM10 在肠道稳态和再生中的作用
- 批准号:
9108378 - 财政年份:2012
- 资助金额:
$ 17.82万 - 项目类别:
Development of ADAM10 Prodomain as a Therapeutic Agent
ADAM10 Prodomain 作为治疗剂的开发
- 批准号:
7674433 - 财政年份:2009
- 资助金额:
$ 17.82万 - 项目类别:
Endogenous Betacellulin Signaling in Beta-cell Biology
Beta 细胞生物学中的内源 Betacellulin 信号转导
- 批准号:
7091459 - 财政年份:2002
- 资助金额:
$ 17.82万 - 项目类别:
Endogenous Betacellulin Signaling in Beta-cell Biology
Beta 细胞生物学中的内源 Betacellulin 信号转导
- 批准号:
6897432 - 财政年份:2002
- 资助金额:
$ 17.82万 - 项目类别:
Endogenous Betacellulin Signaling in Beta-cell Biology
Beta 细胞生物学中的内源 Betacellulin 信号转导
- 批准号:
6574863 - 财政年份:2002
- 资助金额:
$ 17.82万 - 项目类别:
Endogenous Betacellulin Signaling in Beta-cell Biology
Beta 细胞生物学中的内源 Betacellulin 信号转导
- 批准号:
6779889 - 财政年份:2002
- 资助金额:
$ 17.82万 - 项目类别:
Endogenous Betacellulin Signaling in Beta-cell Biology
Beta 细胞生物学中的内源 Betacellulin 信号转导
- 批准号:
6665328 - 财政年份:2002
- 资助金额:
$ 17.82万 - 项目类别:
相似海外基金
Understanding how exocrine-derived signals promote beta cell growth
了解外分泌信号如何促进 β 细胞生长
- 批准号:
10750765 - 财政年份:2024
- 资助金额:
$ 17.82万 - 项目类别:
Graft localized drug delivery to augment beta cell replacement therapies for diabetes
移植局部药物递送以增强糖尿病的β细胞替代疗法
- 批准号:
480374 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Operating Grants
Sustaining functional maturity of pancreatic beta cell through nutritional control
通过营养控制维持胰腺β细胞的功能成熟
- 批准号:
23H03304 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Beta cell rest を目指した新たな2型糖尿病治療法の確立
建立针对 β 细胞休息的新型 2 型糖尿病治疗方法
- 批准号:
23K07959 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PITPNA in pancreatic beta-cell dysfunction and diabetes pathogenesis
PITPNA 在胰腺 β 细胞功能障碍和糖尿病发病机制中的作用
- 批准号:
10636228 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Nutrient-sensor O-GlcNAc Transferase Regulation of Autophagy in Homeostatis of Pancreatic Beta-cell Mass and Function
营养传感器 O-GlcNAc 转移酶对胰腺 β 细胞质量和功能稳态中自噬的调节
- 批准号:
10907874 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
The Influence of Developmental Exposure to Maternal Overnutrition and Metformin on Offspring Mitochondrial Health and Beta Cell Function
发育期暴露于母亲营养过剩和二甲双胍对后代线粒体健康和 β 细胞功能的影响
- 批准号:
10601500 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
New strategies in cell replacement therapies for diabetes: role of USP7 in iPSC and adult organoids beta cell differentiation
糖尿病细胞替代疗法的新策略:USP7 在 iPSC 和成体类器官 β 细胞分化中的作用
- 批准号:
MR/X01813X/1 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Research Grant
Effect of Dietary Carbohydrate on Diabetes Control and Beta Cell Function in Children with Newly Diagnosed Diabetes.”
膳食碳水化合物对新诊断糖尿病儿童的糖尿病控制和 β 细胞功能的影响。
- 批准号:
10637032 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Development of platforms for beta cell-specific delivery and ligand discovery
开发β细胞特异性递送和配体发现平台
- 批准号:
10738505 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别: